Clinical TrialsSearch results
Number of results: 67160
Completed
- A Phase 1, Single-Dose, Multiple-Dose, Food Effect and Drug-Drug Interaction Study of BPN14770
- Health Condition
- Nagata Tsutae
- 2020-11-06
Completed
- A Phase 1/2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults and elderly subjects
- Prevention of COVID-19
- Inoguchi Akihiro
- 2021-03-10
Completed
- A Phase 2 Trial of ARGX-113 PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- CIDP
- Tsuruyama Eri
- 2021-03-12
Completed
- A Phase 2 study of concurrent combination therapy of TFTD (TAS-102) and bevacizumab in patients of more than 70 years of age with unresectable, advanced/recurrent colorectal cancer (KSCC 1602)
- Colorectal Cancer
- Oki Eiji
- 2019-03-20
Completed
- A Phase 2 Study of Osimertinib in combination with Platinum-pemetrexed in patients with EGFR-mutated Advanced non-small cell Lung cancer.
- Non-squamous non-small cell lung cancer
- Kobayashi Kunihiko
- 2019-03-11
Completed
- A phase 2 study of osimertinib in elderly patients with non-small-cell lung cancer
- advanced / recurrent non-small cell lung cancer (NSCLC)
- Uchino Junji
- 2018-09-03
Completed
- A phase 2 study of VLPCOV-01 in COVID-19 vaccinated healthy subjects
- Prevention of infectious disease caused by SARS-CoV-2
- Sato Nobuaki
- 2022-09-12
Completed
- A Phase 2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults
- Prevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)
- Inoguchi Akihiro
- 2021-10-29
Completed
- A Phase 2 Study to Evaluate the Efficacy and Safety of BPN14770 in Participants with Mild Alzheimer's Disease
- mild Alzheimer's disease
- Nagata - Tsutae
- 2021-06-14
Completed
- A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects with Moderate to Severe Atopic Dermatitis.
- Moderate to severe Atopic dermatitis (AD)
- Changliang Zhang
- 2021-05-25